Skip to main content
. 2010 Jun 15;4:207–213. doi: 10.2147/ce.s6003

Table 2.

Phase II data for nilotinib second-line to imatinib failure

Disease n % Response
Overall survival
CHR Cytogenetic response
Major Complete
CML Chronic 321 77 57 41 91% (18 months)
CML Accelerated 136 26 31 19 81% (12 months)
CML Blastic 136 11 40 29 42% (12 months)

Abbreviations: CHR, complete hematologic response; CML, chronic myeloid leukemia.